|
Market Cap (5-Jun) $102,067,456 (1,050th) |
Close (30-Jun) $0.062 |
Volume (30-Jun) 526,676 |
Shortsold (26-May) 683,172 (0.11%) (444th) |
|
52w High $0.67 |
52w Low $0.165 |
P/E 10.78 |
EPS -0.03 |
DXB released this announcement to the ASX on 11 January 2022, 9:50. The announcement is marked as price sensitive, and is 5 page(s) in length and 463.32kb in size.
You can view all announcements from DXB and see how they appear on a price chart on the announcements page.
At the date of this announcement, DXB was 0.001% short sold according to ASIC data. It was ranked the 655th most shorted stock on the ASX. It is now ranked as the 444th most shorted stock on the ASX with 0.114% of total shares short sold as of the latest reported data (26 May 2026).
| Other Recent Announcements from DXB | |
|---|---|
| Application for quotation of securities - DXB | 29 June 2023, 9:01 |
| Application for quotation of securities - DXB | 29 June 2023, 9:00 |
| Application for quotation of securities - DXB | 29 June 2023, 8:59 |
| Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India | 11 January 2022, 9:50 |
| Ethics Approval in Australia for Phase 3 COVID-19 Study | 23 December 2021, 9:16 |
| Dimerix Receives Further MRFF Funding for DMX-200 | 22 December 2021, 9:38 |
| DSMB Recommends Continuation of Ph3 COVID-19 Study in Europe | 16 December 2021, 12:12 |
You must be logged in to post a reply.
Dimerix 